Eisai Co., Ltd. (OTCPK:ESAIY) Disscusses on Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 Transcript
Company Participants
Katsutoshi Ido – VP, Chief Scientific Officer & Head of DHBL Discoverry
Conference Call Participants
Hidemaru Yamaguchi – Citigroup Inc., Research Division
Seiji Wakao – JPMorgan Chase & Co, Research Division
Fumiyoshi Sakai – UBS Investment Bank, Research Division
Shinichiro Muraoka – Morgan Stanley, Research Division
Akinori Ueda – Goldman Sachs Group, Inc., Research Division
Miki Sogi – Sanford C. Bernstein & Co., LLC., Research Division
Kazuaki Hashiguchi – Daiwa Securities Co. Ltd., Research Division
Hiroshi Wada – SMBC Nikko Securities Inc., Research Division
Unknown Attendee
Presentation
Unknown Executive
Thank you very much for taking your time. We would now like to begin oral presentation of highlight of E2086 from World Sleep 2025 oral presentation. This is a virtual session. Please check our website for presentation material.
In Singapore this week, World Sleep 2025 was held. E2086 Phase I study results were presented in oral presentation. The highlight of the presentation will be given today, and questions will also be taken to deepen understanding of the audience of E2086. Presentation will be given by Dr. Katsutoshi Ido, Chief Scientific Officer. Dr. Ido, please.
Katsutoshi Ido
VP, Chief Scientific Officer & Head of DHBL Discoverry
Good morning, everyone. I am Ido. I assume the role of the Chief Scientific Officer in April. Thank you very much for joining us today.
Since I joined the company in 2003, I have worked as a biologist in the research institute in Tsukuba and Cambridge in Massachusetts, focusing on neurology drug discovery. While in Cambridge, I was also served as the Head of the Biotech Investment division for [ 2 ] years, and I was appointed as CSO this spring.
E2086, I will introduce today, is a compound we
#Eisai #Lemborexant #Orexin #Receptor #Agonist #E2086 #World #Sleep